liothyronine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1585 6893-02-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • liothyronine
  • liothyronine sodium
  • triiodothyronine
  • liothyronin
A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
  • Molecular weight: 650.98
  • Formula: C15H12I3NO4
  • CLOGP: 2.63
  • LIPINSKI: 1
  • HAC: 5
  • HDO: 3
  • TPSA: 92.78
  • ALOGS: -4.52
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
60 mcg O
60 mcg P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.00 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ

Approvals:

DateAgencyCompanyOrphan
May 8, 1956 FDA KING PHARMS R AND D

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypothyroidism 78.92 13.93 64 11499 31274 46643225
Sensitisation 47.72 13.93 14 11549 683 46673816
Weight increased 47.43 13.93 117 11446 164356 46510143
Tri-iodothyronine increased 42.60 13.93 9 11554 109 46674390
Polycystic ovaries 42.03 13.93 15 11548 1369 46673130
Ejection fraction 41.01 13.93 12 11551 580 46673919
Urine chloride decreased 39.45 13.93 8 11555 78 46674421
Palpitations 34.29 13.93 74 11489 95185 46579314
Hyperthyroidism 33.95 13.93 26 11537 11685 46662814
Urine sodium decreased 33.93 13.93 8 11555 164 46674335
Nephrectomy 33.37 13.93 10 11553 525 46673974
Blood thyroid stimulating hormone increased 31.30 13.93 19 11544 5850 46668649
Sleep disorder due to a general medical condition 28.64 13.93 15 11548 3484 46671015
Headache 27.90 13.93 208 11355 478144 46196355
Suicidal ideation 26.53 13.93 49 11514 56333 46618166
Product odour abnormal 25.99 13.93 10 11553 1126 46673373
Product quality issue 24.88 13.93 37 11526 35611 46638888
Product substitution issue 24.47 13.93 24 11539 15007 46659492
Blood thyroid stimulating hormone decreased 24.11 13.93 14 11549 3975 46670524
Rhinitis allergic 23.76 13.93 17 11546 6891 46667608
Feeling abnormal 23.28 13.93 76 11487 124984 46549515
Fatigue 23.17 13.93 241 11322 608456 46066043
Sleep apnoea syndrome 23.10 13.93 28 11535 22173 46652326
Blood thyroid stimulating hormone abnormal 23.03 13.93 8 11555 674 46673825
Blood test abnormal 23.02 13.93 19 11544 9501 46664998
Thyroid function test abnormal 21.34 13.93 12 11551 3206 46671293
Nail toxicity 19.44 13.93 6 11557 348 46674151
Burning sensation 18.91 13.93 37 11526 44374 46630125
Death 18.82 13.93 34 11529 335514 46338985
Madarosis 18.56 13.93 9 11554 1777 46672722
Carpal tunnel syndrome 18.15 13.93 21 11542 15838 46658661
Rheumatoid arthritis 17.76 13.93 20 11543 240195 46434304
Insomnia 17.49 13.93 84 11479 164840 46509659
Nail growth abnormal 17.42 13.93 6 11557 493 46674006
Thyroid cancer 16.79 13.93 11 11552 3867 46670632
Fibromyalgia 16.29 13.93 31 11532 36432 46638067
Product colour issue 15.86 13.93 6 11557 645 46673854
Tri-iodothyronine decreased 15.48 13.93 4 11559 121 46674378
Recalled product 15.32 13.93 7 11556 1210 46673289
Alopecia 15.30 13.93 80 11483 162334 46512165
Thyrotoxic crisis 15.08 13.93 6 11557 739 46673760
Vascular injury 14.35 13.93 6 11557 838 46673661
Acute kidney injury 14.03 13.93 23 11540 235832 46438667

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Performance enhancing product use 48.02 22.01 8 1998 101 29950371
Rhythm idioventricular 46.51 22.01 9 1997 274 29950198
Secondary hypogonadism 45.83 22.01 9 1997 296 29950176
Autoimmune thyroiditis 39.96 22.01 10 1996 1010 29949462
Loose associations 37.67 22.01 6 2000 56 29950416
Thyrotoxic periodic paralysis 37.39 22.01 6 2000 59 29950413
Glucose tolerance decreased 35.92 22.01 6 2000 77 29950395
Choroidal detachment 32.58 22.01 7 1999 361 29950111
Sinus arrest 31.46 22.01 9 1997 1511 29948961
Feelings of worthlessness 30.50 22.01 6 2000 199 29950273
Thunderclap headache 29.73 22.01 5 2001 67 29950405
Haematocrit increased 26.26 22.01 8 1998 1668 29948804
Pressure of speech 25.91 22.01 6 2000 436 29950036
Hyperthyroidism 25.74 22.01 12 1994 8086 29942386
Pain 23.97 22.01 42 1964 172599 29777873
Reversible cerebral vasoconstriction syndrome 23.58 22.01 5 2001 242 29950230
Blood prolactin decreased 22.88 22.01 5 2001 279 29950193

Pharmacologic Action:

SourceCodeDescription
ATC H03AA02 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
THYROID THERAPY
THYROID PREPARATIONS
Thyroid hormones
ATC H03AA03 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
THYROID THERAPY
THYROID PREPARATIONS
Thyroid hormones
FDA CS M0021977 Triiodothyronine
FDA EPC N0000175946 l-Triiodothyronine
CHEBI has role CHEBI:60311 thyroid hormones
CHEBI has role CHEBI:75771 mus musculus metabolite
CHEBI has role CHEBI:77746 h. sapiens metabolites

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Goiter indication 3716002 DOID:12176
Myxedema coma indication 21263006
Hypothyroidism indication 40930008 DOID:1459
Myxedema indication 43153006 DOID:11634
Congenital hypothyroidism indication 190268003 DOID:0050328
Simple goiter indication 267369002
Malignant tumor of thyroid gland indication 363478007 DOID:1781
T3 Suppression for Thyroid Function Test indication
Mild Hypothyroidism indication
Diagnostic Test for Thyroid Dysfunction indication
Myocardial infarction contraindication 22298006 DOID:5844
Thyrotoxic crisis contraindication 29028009 DOID:12837
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Osteoporosis contraindication 64859006 DOID:11476
Diabetes mellitus contraindication 73211009 DOID:9351
Hypopituitarism contraindication 74728003 DOID:9406
Angina pectoris contraindication 194828000
Osteopenia contraindication 312894000
Primary adrenocortical insufficiency contraindication 373662000
Disorder of coronary artery contraindication 414024009

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.08 acidic
pKa2 8.12 acidic
pKa3 8.77 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Thyroid hormone receptor alpha Nuclear hormone receptor AGONIST Kd 10.24 CHEMBL CHEMBL
Thyroid hormone receptor beta Nuclear hormone receptor AGONIST Ki 10.10 CHEMBL CHEMBL
THAP domain-containing protein 1 Unclassified EC50 9 WOMBAT-PK
Proliferating cell nuclear antigen Unclassified IC50 5.44 CHEMBL
GABA-A receptor; anion channel Ion channel IC50 4.64 CHEMBL
Adenosine receptor A1 GPCR Ki 6.62 DRUG MATRIX
Cytochrome P450 2C9 Enzyme EC50 6.30 WOMBAT-PK
GABA-A receptor; anion channel Ion channel EC50 5.15 CHEMBL
Thyroid hormone receptor beta Transcription factor IC50 8.74 CHEMBL

External reference:

IDSource
4022167 VUID
N0000020173 NUI
D01011 KEGG_DRUG
55-06-1 SECONDARY_CAS_RN
4018002 VANDF
4022167 VANDF
C0041014 UMLSCUI
CHEBI:18258 CHEBI
T3 PDB_CHEM_ID
CHEMBL1544 ChEMBL_ID
CHEMBL1201119 ChEMBL_ID
D014284 MESH_DESCRIPTOR_UI
DB00279 DRUGBANK_ID
653 INN_ID
06LU7C9H1V UNII
5920 PUBCHEM_CID
2634 IUPHAR_LIGAND_ID
10814 RXNORM
1964 MMSL
4982 MMSL
d00658 MMSL
002133 NDDF
004882 NDDF
126204001 SNOMEDCT_US
350358003 SNOMEDCT_US
61275002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0093-2178 TABLET 25 ug ORAL ANDA 26 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0093-2179 TABLET 5 ug ORAL ANDA 26 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0093-2180 TABLET 50 ug ORAL ANDA 26 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 16590-303 TABLET 50 1 ORAL ANDA 13 sections
Liothyronine sodium HUMAN PRESCRIPTION DRUG LABEL 1 16714-166 TABLET 5 ug ORAL ANDA 24 sections
Liothyronine sodium HUMAN PRESCRIPTION DRUG LABEL 1 16714-167 TABLET 25 ug ORAL ANDA 24 sections
Liothyronine sodium HUMAN PRESCRIPTION DRUG LABEL 1 16714-168 TABLET 50 ug ORAL ANDA 24 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 33261-964 TABLET 5 ug ORAL ANDA 25 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 39822-0151 INJECTION, SOLUTION 10 ug INTRAVENOUS ANDA 25 sections
Triostat HUMAN PRESCRIPTION DRUG LABEL 1 42023-120 INJECTION 10 ug INTRAVENOUS NDA 25 sections
NP Thyroid 15 HUMAN PRESCRIPTION DRUG LABEL 2 42192-327 TABLET 2.25 ug ORAL unapproved drug other 23 sections
NP Thyroid 120 HUMAN PRESCRIPTION DRUG LABEL 2 42192-328 TABLET 18 ug ORAL unapproved drug other 22 sections
NP Thyroid 30 HUMAN PRESCRIPTION DRUG LABEL 2 42192-329 TABLET 4.50 ug ORAL unapproved drug other 22 sections
NP Thyroid 60 HUMAN PRESCRIPTION DRUG LABEL 2 42192-330 TABLET 9 ug ORAL unapproved drug other 22 sections
NP Thyroid 90 HUMAN PRESCRIPTION DRUG LABEL 2 42192-331 TABLET 13.50 ug ORAL unapproved drug other 22 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42291-417 TABLET 5 ug ORAL ANDA 27 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42291-418 TABLET 25 ug ORAL ANDA 27 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42291-419 TABLET 50 ug ORAL ANDA 27 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42794-018 TABLET 5 ug ORAL ANDA 27 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42794-019 TABLET 25 ug ORAL ANDA 27 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 42794-020 TABLET 50 ug ORAL ANDA 27 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 43063-884 TABLET 25 ug ORAL ANDA 27 sections
NP Thyroid 60 HUMAN PRESCRIPTION DRUG LABEL 2 45865-566 TABLET 9 ug ORAL unapproved drug other 22 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 50090-3131 TABLET 5 ug ORAL ANDA 27 sections
NP Thyroid 30 HUMAN PRESCRIPTION DRUG LABEL 2 50090-4376 TABLET 4.50 ug ORAL unapproved drug other 22 sections
NP Thyroid 60 HUMAN PRESCRIPTION DRUG LABEL 2 50090-5216 TABLET 9 ug ORAL unapproved drug other 22 sections
NP Thyroid 90 HUMAN PRESCRIPTION DRUG LABEL 2 50090-5229 TABLET 13.50 ug ORAL unapproved drug other 22 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 51407-384 TABLET 5 ug ORAL ANDA 27 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 51407-385 TABLET 25 ug ORAL ANDA 27 sections
Liothyronine Sodium HUMAN PRESCRIPTION DRUG LABEL 1 51407-386 TABLET 50 ug ORAL ANDA 27 sections